Akihiro Eguchi
Forsker
Olsen Group
Blegdamsvej 3B
2200 København N
There is no presentation filled.
ID: 259144034
Most downloads
-
37
downloads
Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
Research output: Contribution to journal › Journal article › peer-review
Published